Potent N-type voltage-gated calcium channel blocker (IC50 = 36 nM). Displays selectivity over K+, Na+ and L-type Ca2+ channels. Prevents tonic seizures in the audiogenic seizure model in vivo.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 599.85. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.67 mL||8.34 mL||16.67 mL|
|5 mM||0.33 mL||1.67 mL||3.33 mL|
|10 mM||0.17 mL||0.83 mL||1.67 mL|
|50 mM||0.03 mL||0.17 mL||0.33 mL|
References are publications that support the biological activity of the product.
Hu et al (1999) Structure-activity relationships of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers. Bioorg.Med.Chem.Letts. 9 2151
If you know of a relevant reference for PD 173212, please let us know.
View Related Products by Product Action
Keywords: PD 173212, PD 173212 supplier, Potent, N-type, Ca2+, channel, blockers, Calcium, CaV, Channels, voltage-gated, voltage-dependent, PD173212, Voltage-gated, 3552, Tocris Bioscience
Citations for PD 173212
Citations are publications that use Tocris products.
Currently there are no citations for PD 173212. Do you know of a great paper that uses PD 173212 from Tocris? Please let us know.
Reviews for PD 173212
There are currently no reviews for this product. Be the first to review PD 173212 and earn rewards!
Have you used PD 173212?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.